

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

CD90-FITC, human

RRID:AB_2660947

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-097-930, RRID:AB_2660947

Antibody Information

URL: http://antibodyregistry.org/AB_2660947

Proper Citation: Miltenyi Biotec Cat# 130-097-930, RRID:AB_2660947

Target Antigen: CD90

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 12-2018; Target Distribution brain, cancer stem cells, endothelial cells, fibroblasts, hematopoietic stem cells, leukemia cells, leukocytes, lymphocytes, mesenchymal stem cells, neurons, ES and iPS cells, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity: Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-117-796. (RRID:AB_2784297).

Antibody Name: CD90-FITC, human

Description: This monoclonal targets CD90

Target Organism: human

Clone ID: DG3

Antibody ID: AB_2660947

Vendor: Miltenyi Biotec

Catalog Number: 130-097-930

Record Creation Time: 20250819T215221+0000

Record Last Update: 20250820T002235+0000

Ratings and Alerts

No rating or validation information has been found for CD90-FITC, human.

Warning: Discontinued: 2021

Discontinued: 12-2018; Target Distribution brain, cancer stem cells, endothelial cells, fibroblasts, hematopoietic stem cells, leukemia cells, leukocytes, lymphocytes, mesenchymal stem cells, neurons, ES and iPS cells, T cells, thymocytes; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-117-796. (RRID:AB_2784297).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chan LH, et al. (2018) PRMT6 Regulates RAS/RAF Binding and MEK/ERK-Mediated Cancer Stemness Activities in Hepatocellular Carcinoma through CRAF Methylation. Cell reports, 25(3), 690.